CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Genetic Testing for Inherited Thrombophilia

This policy governs coverage and medical necessity determinations for genetic testing for inherited thrombophilias (including Factor V Leiden, prothrombin/Factor II, and MTHFR variants) for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyGenetic Testing for Inherited Thrombophilia

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJun 1, 2024

Next Review DateJun 3, 2024

Key ActionVerify member benefits and eligibility with the provider call center before ordering testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

3Gene targets named

1/1000VTE incidence

30% (10y)VTE recurrence

Coverage Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not Medically Necessary / Not Covered

Covered when ALL of the following are met:

Primary coverage stance: Genetic testing for inherited thrombophilia (including Factor V Leiden, prothrombin/Factor II variants, and MTHFR variants) is not covered / not medically necessary because the evidence is insufficient to demonstrate an improvement in net health outcome.

Policy cites modest associations between variants and VTE risk, limited clinical utility for guiding prophylactic anticoagulation or duration, and uncertain utility for MTHFR testing.

Genetic testing for inherited thrombophilia — including testing for Factor V Leiden (F5, Leiden variant), prothrombin/Factor II (F2, G20210A), and common MTHFR variants — is not covered / not medically necessary. The policy concludes that the evidence is insufficient to demonstrate that testing improves net health outcomes and therefore does not meet criteria for coverage.

Professional recommendations and evidence reviews question routine, population-based, or indiscriminate testing for Factor V Leiden and prothrombin (G20210A) mutations in some adult populations. EGAPP and other working groups have issued guidance advising against routine testing in adults without specific clinical indications.

Rationale: although FVL and prothrombin variants are associated with an increased risk of venous thromboembolism, the magnitude of risk is generally modest and the absolute risk remains low. Available evidence does not demonstrate that identifying these variants leads to changes in management that improve net health outcomes; prophylactic anticoagulation informed by testing carries bleeding risks that may outweigh benefits. For MTHFR variants, both clinical validity and clinical utility are uncertain. Consequently, testing is considered not medically necessary.

Guideline-level guidance and working group recommendations are cited in support of the policy position. EGAPP and related guidance documents recommend against routine testing for Factor V Leiden and prothrombin mutations in certain adult groups (for example, unselected adults with idiopathic VTE and their adult family members), reflecting limited evidence that testing changes clinical outcomes.

Clinical Situations Discussed

Evaluation of a patient with established thrombosis when results might change anticoagulant management

Testing in the following clinical scenario is discussed in the literature but is not supported for coverage by this policy:

Clinical scenario: Evaluation of a patient with established thrombosis for consideration of a change in anticoagulant management based on genetic test results.

Although considered in studies and reviews, available evidence does not define a role for thrombophilia testing to guide initiation or duration of anticoagulation; thus testing is not covered for this indication.

Evaluation of patients at high risk for thrombosis (e.g., pregnancy, planned major surgery, exogenous hormone use)

Mentioned as a potential context for testing but not supported for coverage:

Clinical scenario: Evaluation of patients considered at high risk for thrombosis (for example, pregnancy, planned major surgery, or exogenous hormone use).

Policy notes these situations in clinical discussions, but evidence does not demonstrate that testing alters management to improve net health outcomes; testing is not covered.

Evaluation of close relatives of patients with documented inherited thrombophilia or consistent family history

Listed as a contemplated use but not supported for coverage by this policy:

Clinical scenario: Evaluation (genetic testing) of close relatives of patients with documented inherited thrombophilia or with a clinical and family history consistent with inherited thrombophilia.

Family testing and cohort studies are cited, but no coverage criteria are provided and routine testing of relatives is not supported given limited demonstrated clinical utility; testing is not covered.

Testing related to diagnosis and management of thromboembolic disorders and evaluation of VTE risk (e.g., FVL, prothrombin G20210A)

Testing related to diagnosis and management of thromboembolic disorders is discussed in guidelines and studies but is not supported for coverage under this policy:

Scope: Genetic testing for common inherited thrombophilia variants (for example, Factor V Leiden [F5 R506Q], prothrombin G20210A [F2], and MTHFR common variants) for diagnosis, risk stratification, or to guide management of venous thromboembolism (VTE).

Multiple clinical studies, meta-analyses, and professional guidelines (CHEST, ACMG, ACOG and related reviews) are cited showing modest association with VTE risk and limited evidence that testing improves clinical outcomes; therefore testing for these purposes is not covered.

Supporting evidence notes

Clinical validity: Presence of FVL or prothrombin variant is associated with increased VTE risk, but magnitude is modest (most odds ratios ~1–2).
See cited cohort and case-control studies.
Clinical utility: Evidence does not demonstrate that thrombophilia testing changes management in a way that improves net health outcomes (eg, decisions on initiation or duration of prophylactic anticoagulation are not defined by current evidence).

Not Covered / Exclusions

Not covered: Genetic testing for inherited thrombophilia — including testing for Factor V Leiden (F5, Leiden variant), prothrombin/Factor II (F2, G20210A), and MTHFR common variants — is explicitly not covered / not medically necessary for the products addressed by this policy.

Not covered: Routine population-based or indiscriminate testing for Factor V Leiden and prothrombin G20210A mutations is questioned by EGAPP and other cited sources and therefore is not supported for coverage.

Billing and Coding

Denial Risk

Provider action — Denial risk / Billing guidance

Services listed below are determined not medically necessary for Commercial products and are not covered for Medicare Advantage Plans. Providers should verify member-specific coverage, benefits, and prior authorization requirements before ordering or billing these tests. Submission of these codes may result in claim denial; document medical necessity if proceeding and verify plan-specific appeal rights.

Affected CPT codes: 81240, 81241, 81291
Action: Verify member-specific benefits and prior authorization; expect denial for Medicare Advantage if billed without coverage determination.

Provider Actions and Notices

Prior Authorization

Prior authorization not applicable

Prior authorization is not required for these genetic tests.

Note

Verify benefits and eligibility with provider call center

Verify member-specific benefits and eligibility by contacting the BCBSRI provider call center before ordering tests to confirm coverage under the member’s contract.

Benefits and eligibility are determined by the member’s subscriber agreement or employer agreement.
Call the provider call center for member-specific benefits information.

Note

Provider note — policy informational; payment not guaranteed

This policy is informational and does not guarantee payment; providers should follow the member’s subscriber agreement and participation agreement provisions when offering services that may be non-covered.

Documentation Required

Procedural requirement when offering non-covered services

If services are determined to be not medically necessary or are non-covered benefits, providers may not charge the member unless the member has been informed and has provided prior written agreement to pay at own expense per participation agreement.

Obtain a written agreement in advance if the member will be charged for non-covered services.
Refer to participation agreement(s) for applicable provisions.

Documentation Required

Benefit verification required — check Evidence of Coverage/Subscriber Agreement

Benefits for not medically necessary or non-covered services can vary by contract; refer to the member’s Evidence of Coverage or Subscriber Agreement to determine applicable coverage rules.

Evidence of Coverage or Subscriber Agreement controls applicable not medically necessary / not covered benefits.

Documentation Required

Verify member benefits & eligibility before ordering

Providers must verify member-specific benefits and eligibility with the BCBSRI provider call center because benefits and eligibility are determined by the member’s subscriber or employer agreement, which supersede this medical policy.

Confirm coverage before ordering testing to avoid unexpected patient liability.
Subscriber/employer agreement supersedes the medical policy.

Denial Risk

Risk of being unable to charge member for non-covered / not medically necessary services

If a test is determined not medically necessary or is a non-covered benefit, the provider may be prohibited from charging the member unless a prior written agreement is obtained; follow participation agreement terms when notifying members and obtaining consent to bill.

Inform the member and obtain written agreement in advance to continue treatment at their own expense if applicable.
Refer to participation agreement(s) for billing provisions.

Clinical Background

Background: Inherited thrombophilias are genetic conditions that increase risk for venous thromboembolism (VTE). In the U.S., VTE incidence is approximately 1 per 1,000 person-years with a lifetime prevalence around 5% and a recurrence risk that can be substantial (about 30% at 10 years). Common inherited thrombophilias include Factor V Leiden, prothrombin G20210A, protein C and S deficiencies, and MTHFR variants.

Definitions

Inherited thrombophilia — definition and examples

DefinitionInherited thrombophilias are clinical conditions caused by genetic defects that alter the amount or function of coagulation proteins and predispose individuals to venous thromboembolism (VTE).

Common examples listedFactor V Leiden (FVL), Prothrombin (Factor II) G20210A variant, Protein C deficiency, Protein S deficiency, Prothrombin deficiency, and MTHFR variants (hyperhomocysteinemia).

Epidemiology noteNot all individuals with an inherited thrombophilia will develop VTE; in patients with recurrent thromboses, prevalence of identifying an inherited thrombophilia ranges ~5%–40%.

Factor V Leiden (FVL) — definition and clinical association

DefinitionFactor V Leiden (FVL) is a variant in the factor V gene that causes activated protein C resistance and is the most common inherited thrombophilia, accounting for up to ~50% of inherited thrombophilia syndromes.

Clinical associationPresence of FVL is associated with an increased risk of subsequent VTE; magnitude of association is typically modest (odds ratios most commonly between 1 and 2), though higher in family members of affected individuals.

Prevalence in recurrent thrombosisEstimated prevalence of FVL in patients with recurrent thrombosis is approximately 12%–40%.

ACMG technical standard for VTE laboratory testing — reference and scope

ScopeTechnical standard covers laboratory testing for factor V Leiden and factor II (prothrombin) variants used in evaluation of inherited thrombophilia and VTE risk assessment.

Use in policyACMG technical standard is cited as laboratory/technical guidance informing test selection and analytic approaches for germline testing of FVL and prothrombin G20210A.

Policy Revision History

2024-06-03policy_reviewLatest

Policy last reviewed (document metadata lists last_review as 2024-06-03).

2024-06-01policy_effective_date

Policy effective date established as 2024-06-01 in document metadata.

2021-12guideline_citation

CHEST guideline update cited: Antithrombotic Therapy for VTE Disease (Second Update of the CHEST Guideline) published Dec 2021.

2018-12technical_standard_citation

ACMG technical standard for venous thromboembolism laboratory testing (Factor V Leiden and factor II) published Dec 2018.

2016-02guideline_citation

CHEST Guideline and Expert Panel Report: Antithrombotic Therapy for VTE Disease published Feb 2016.

2012-02guideline_citation

American College of Chest Physicians evidence-based guidelines (executive summary) published Feb 2012 cited in references.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyGenetic Testing for Inherited Thrombophilia

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJun 1, 2024

Next Review DateJun 3, 2024

Key ActionVerify member benefits and eligibility with the provider call center before ordering testing.

SourceLink

On This Page

Prophylactic anticoagulation carries bleeding risk that may outweigh benefits when guided by these test results.

MTHFR testing: Clinical validity and clinical utility are uncertain; routine testing for MTHFR variants is not supported.

Guidance and evidence cited do not support MTHFR testing to improve outcomes.